N,N-二甲基-1H-吡唑-1-磺酰胺 | 133228-21-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: N,N-二甲基-1H-吡唑-1-磺酰胺
• 中文别名: 1-(二甲基氨基磺酰基)吡唑；1-(N,N-二甲基-磺酰基)吡唑
• 英文名称: N,N-dimethyl-1H-pyrazole-1-sulfonamide
• 英文别名: 1-(N,N-dimethyl-sulfamoyl)pyrazole；N,N-dimethylpyrazole-1-sulfonamide；N-dimethylsulfamoylpyrazole；pyrazole-1-sulphonic acid dimethylamide；pyrazole-1-sulfonic acid dimethylamide；1-(N,N-dimethylsulfamoyl)pyrazole；1-(Dimethylsulfamoyl)pyrazole
• CAS: 133228-21-4
• 化学式: C₅H₉N₃O₂S
• 分子量: 175.211
• InChiKey: RFYSRCRZAGKOIY-UHFFFAOYSA-N

物化性质

• 熔点：
  118.5 °C
• 沸点：
  287.4±23.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(Dimethylsulfamoyl)pyrazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(Dimethylsulfamoyl)pyrazole
CAS number: 133228-21-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H9N3O2S
Molecular weight: 175.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N,N-二甲基-1H-吡唑-1-磺酰胺 在 正丁基锂 、 1,2-二溴四氯乙烷 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 2.0h， 以57%的产率得到5-溴-N,N-二甲基吡唑-1-磺酰胺
  参考文献：
  名称：

  利用活性位点突变受体鉴定有效的和选择性的非典型5-HT 2C受体激动剂。

  摘要：

  5-HT 2C受体的拮抗作用是药理学减轻体重的最深入研究和临床证明的机制之一。对密切相关的5-HT 2A和5-HT 2B受体的选择性至关重要，因为已证明它们的活化会导致不良的副作用和重大的安全隐患。在此通讯中，我们报告了一种新的筛选范例的开发，该范例利用了活性位点突变体D134A（D3.32）5-HT 2C受体来鉴定非典型激动剂结构。我们还报告了5-HT 2C的新型非碱性杂环酰胺激动剂的发现和优化。围绕筛选结果的SAR调查为5-HT提供了多种有效的激动剂2C具有对相关5-HT 2A和5-HT 2B受体亚型的高选择性。通过用各种五元和六元杂环取代酰胺进行进一步优化，导致鉴定出6-（1-乙基-3-（喹啉-8-基）-1 H-吡唑-5-基）哒嗪-3-胺（69）。老鼠口服给药69可减少随意采食模型中的食物摄入量，而选择性5-HT 2C拮抗剂可完全逆转这种情况。

  DOI：

  10.1021/acs.jmedchem.7b00385
• 作为产物：
  描述：

  二甲胺基磺酰氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 以82%的产率得到N,N-二甲基-1H-吡唑-1-磺酰胺
  参考文献：
  名称：

  WO2006/91671

  摘要：

  公开号：

文献信息

• Pyrazole derivatives having herbicidal activity and their use
  申请人：Sankyo Company, Limited

  公开号：US05424279A1

  公开（公告）日：1995-06-13

  Compounds of formula (I): ##STR1## (in which: R.sup.1 and R.sup.2 are each hydrogen, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, alkoxy, aryl or pyridyl, or R.sup.1 and R.sup.2 together represent alkylene; A and B are each hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, alkylthio, alkylsulfonyl, dialkylsulfamoyl, aliphatic carboxylic acyl, carboxy, --CONR.sup.a R.sup.b where R.sup.a and R.sup.b are each hydrogen or alkyl, formyl or cyano groups; D represents optionally substituted phenyl, benzyl, pyridyl or pyrimidinyl; and n is 0, 1 or 2; and salts and esters thereof) have valuable herbicidal properties, and, since they are totally innocuous to rice plants, are especially useful for the treatment of paddy fields.

  公式(I)的化合物：##STR1##（其中：R.sup.1和R.sup.2各自是氢，可选地取代的烷基，可选地取代的烯基，炔基，烷氧基，芳基或吡啶基，或者R.sup.1和R.sup.2共同代表亚烷基；A和B各自是氢，卤素，可选地取代的烷基，可选地取代的烯基，可选地取代的烷氧基，烷基亚砜基，烷基亚磺酰基，二烷基亚磺酰氨基，脂肪族羧酸酰基，羧基，--CONR.sup.a R.sup.b其中R.sup.a和R.sup.b各自是氢或烷基，甲酰基或腈基团；D代表可选地取代的苯基，苄基，吡啶基或嘧啶基；n是0，1或2；以及它们的盐和酯）具有宝贵的除草性质，并且由于它们对水稻植物完全无害，因此特别适用于稻田的处理。
• [EN] THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY<br/>[FR] THIAZOLOPYRIMIDINONES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR NMDA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015052226A1

  公开（公告）日：2015-04-16

  The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.

  本发明涉及某些噻唑吡咯嘧啶酮化合物，用于调节NMDA受体活性，包括这些化合物的药物组合物以及治疗神经和精神疾病的方法。
• [EN] THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS<br/>[FR] THIÉNOPYRIMIDINES EN TANT QU'INHIBITEURS DE LA KINASE CDC7
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010101302A1

  公开（公告）日：2010-09-10

  The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

  本发明涉及一种由式(I)表示的化合物，其中每个符号如规范中定义，或其盐，或其前药，用于预防或治疗癌症。
• [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
  申请人：NIMBUS LAKSHMI INC

  公开号：WO2017040757A1

  公开（公告）日：2017-03-09

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物用于抑制TYK2和治疗TYK2介导的疾病的方法。
• Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones
  作者：Osamu Kurasawa、Yuya Oguro、Tohru Miyazaki、Misaki Homma、Kouji Mori、Kenichi Iwai、Hideto Hara、Robert Skene、Isaac Hoffman、Akihiro Ohashi、Sei Yoshida、Tomoyasu Ishikawa、Nobuo Cho

  DOI：10.1016/j.bmc.2017.02.021

  日期：2017.4

  with Cdc7 homology model. The pharmacophore model provided a minimum structural motif of Cdc7 inhibitor, by which preliminary medicinal chemistry efforts identified a dihydrothieno[3,2-d]-pyrimidin-4(1H)-one scaffold having a heteroaromatic hinge-binding moiety. The structure-activity relationship (SAR) studies resulted in the discovery of new, potent, and selective Cdc7 inhibitors 14a, c, e. Furthermore

  细胞分裂周期7​​（Cdc7）是一种丝氨酸/苏氨酸激酶，在调节DNA复制过程中起重要作用。一项遗传研究表明，Cdc7抑制可以p53依赖性方式诱导选择性肿瘤细胞死亡，这表明Cdc7是治疗癌症的诱人靶标。为了鉴定一类新的有效Cdc7抑制剂，我们基于对具有Cdc7同源性模型的已知抑制剂的计算机对接分析，建立了一个推定的药效团模型。药效团模型提供了Cdc7抑制剂的最小结构基序，据此初步的医学化学工作确定了具有杂芳族铰链结合部分的二氢噻吩并[3,2-d]-嘧啶-4（1H）-一个支架。构效关系（SAR）研究导致发现了新的，有效的，和选择性的Cdc7抑制剂14a，c，e。此外，通过利用与Cdc7和ROCK2晶体结构的对接研究，讨论了14c，e对Cdc7相对于Rho相关蛋白激酶1（ROCK1）的高选择性。